151 related articles for article (PubMed ID: 1532507)
21. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot.
Costantini S; Anserini P; Valenzano M; Remorgida V; Venturini PL; De Cecco L
Eur J Obstet Gynecol Reprod Biol; 1990 Oct; 37(1):63-9. PubMed ID: 2142921
[TBL] [Abstract][Full Text] [Related]
22. Deferred versus immediate surgery for uterine fibroids: clinical trial results.
Audebert AJ; Madenelat P; Querleu D; Pontonnier G; Racinet C; Renaud R; Gillet JY; Raudrant D; Lansac J; Brettes JP
Br J Obstet Gynaecol; 1994 May; 101 Suppl 10():29-32. PubMed ID: 8199102
[No Abstract] [Full Text] [Related]
23. The management of leiomyoma uteri by GnRH analogues.
Giorgino FL; Cetera C
Clin Exp Obstet Gynecol; 1991; 18(2):137-43. PubMed ID: 1833095
[TBL] [Abstract][Full Text] [Related]
24. Fibroids: overview of current and future treatment options.
Benagiano G; Morini A; Primiero FM
Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():18-22. PubMed ID: 1554684
[No Abstract] [Full Text] [Related]
25. The place of GnRH agonists in the treatment of endometriosis and fibroids by advanced endoscopic techniques.
Donnez J; Nisolle M; Grandjean P; Gillerot S; Clerckx F
Br J Obstet Gynaecol; 1992 Feb; 99 Suppl 7():31-3. PubMed ID: 1532508
[No Abstract] [Full Text] [Related]
26. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot.
Leone M; Cucuccio S; Venturini PL; Valenzano-Menada M; Messeni Leone M; De Cecco L
Horm Metab Res; 1991 Sep; 23(9):442-5. PubMed ID: 1835956
[TBL] [Abstract][Full Text] [Related]
27. Zoladex in advanced breast cancer.
Robertson JF; Nicholson RI; Walker KJ; Blamey RW
Horm Res; 1989; 32 Suppl 1():206-8. PubMed ID: 2533151
[TBL] [Abstract][Full Text] [Related]
28. Monthly implant of luteinizing hormone-releasing hormone agonist: a practical therapeutic approach for sex-steroid dependent gynecologic diseases.
Lemay A
Fertil Steril; 1987 Jul; 48(1):10-2. PubMed ID: 2954859
[No Abstract] [Full Text] [Related]
29. Sequential Gn-RH superagonist and medroxyprogesterone acetate treatment of uterine leiomyomata.
Benagiano G; Morini A; Aleandri V; Piccinno F; Primiero FM; Abbondante G; Elkind-Hirsch K
Int J Gynaecol Obstet; 1990 Dec; 33(4):333-43. PubMed ID: 1979288
[TBL] [Abstract][Full Text] [Related]
30. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
31. Management of fibroids.
Altchek A
Curr Opin Obstet Gynecol; 1992 Jun; 4(3):463-71. PubMed ID: 1535799
[TBL] [Abstract][Full Text] [Related]
32. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist.
Lumsden MA; West CP; Bramley T; Rumgay L; Baird DT
Br J Obstet Gynaecol; 1988 Dec; 95(12):1299-304. PubMed ID: 2975953
[TBL] [Abstract][Full Text] [Related]
33. Role of goserelin-depot in the clinical management of uterine fibroids.
Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB
Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879
[TBL] [Abstract][Full Text] [Related]
34. [Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
Vavra N; Salzer H; Sevelda P; Breitenecker G; Czerwenka K; Kucera H
Gynakol Rundsch; 1990; 30(3):133-43. PubMed ID: 2147161
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis.
Friedman AJ; Lobel SM; Rein MS; Barbieri RL
Am J Obstet Gynecol; 1990 Oct; 163(4 Pt 1):1114-9. PubMed ID: 2145765
[TBL] [Abstract][Full Text] [Related]
36. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions.
Chrisp P; Goa KL
Drugs; 1991 Feb; 41(2):254-88. PubMed ID: 1709853
[TBL] [Abstract][Full Text] [Related]
37. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability.
Caird LE; West CP; Lumsden MA; Hannan WJ; Gow SM
Hum Reprod; 1997 Mar; 12(3):436-40. PubMed ID: 9130735
[TBL] [Abstract][Full Text] [Related]
38. Cornual fibroids: a conservative approach to restoring tubal patency using a gonadotropin-releasing hormone agonist (goserelin) with successful pregnancy.
Gardner RL; Shaw RW
Fertil Steril; 1989 Aug; 52(2):332-4. PubMed ID: 2526755
[TBL] [Abstract][Full Text] [Related]
39. GnRHa and steroid add-back therapy for uterine myoma.
Ishimaru T; Samejima T; Masuzaki H
Int J Gynaecol Obstet; 1995 Feb; 48(2):221. PubMed ID: 7789601
[No Abstract] [Full Text] [Related]
40. Zoladex plus tamoxifen versus Zoladex alone in pre- and peri-menopausal metastatic breast cancer.
Nicholson RI; Walker KJ; McClelland RA; Dixon A; Robertson JF; Blamey RW
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):989-95. PubMed ID: 2149510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
